Funder: National Institutes of Health

Due Dates: August 6, 2025 (Letter of Intent) | September 5, 2025 (Application) | December 6, 2025 (Letter of Intent) | January 5, 2026 (Application) | March 6, 2026 (Letter of Intent) | April 5, 2026 (Application) | August 6, 2026 (Letter of Intent) | September 5, 2026 (Application)

Funding Amounts: Phase I: up to $700,000 total costs (max $500,000/year, up to 2 years); Phase II: up to $3,000,000 total costs (max $1,500,000/year, up to 3 years); typical awards are lower; see details below.

Summary: Supports U.S. small businesses in conducting exploratory clinical trials for neurological products aligned with NINDS priorities, including drugs, biologics, devices, diagnostics, and therapies.

Key Information: Clinical trial is required; only STTR Phase II and Fast-Track applications are accepted (Phase I only as part of Fast-Track); regulatory documentation is mandatory at submission.